A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Latest Information Update: 08 Jul 2025
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 11 Mar 2025 Status changed from active, no longer recruiting to completed.
- 28 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2020 Status changed from not yet recruiting to recruiting.